Medico-Chirurgo. Specialista in Oncologia. Dirigente medico oncologo ASL Caserta. Dottoranda Medicina Traslazionale Università della Campania Luigi Vanvitelli.
With 6 FDA approvals in breast cancer already in 2026, it was time to update the breast cancer treatment algorithms. It's a great problem to have when innovation is moving so fast that it's hard to keep up #bcsm@OncoAlert@DFCI_BreastOnc
Nasce Associazione Bryo: un team di giovani oncologi con un obiettivo chiaro: rivoluzionare la divulgazione sul tumore mammario. 🧬🎀
Meno distanze, più scienza: uniamo l'aggiornamento medico al coinvolgimento attivo delle pazienti. 🚀
🌐 https://t.co/kTIU6bhWCn
At #ESMO24 results of the DETECT V trial
➡️ Omission of CT in HER2+ HR+ mBC might be an effective alternative treatment option, and the addition of ribociclib may further ⬆️ survival
@OncoAlert
Post KN522 critical to study who needs or does not need IO, optimal duration, and chemo options. Studies ongoing! @OncoAlert#ESMO24@stolaney1 and many more.
Adj Ribociclib showed 5.1% iDFS improvement in <40 y BC pts. Safety profile and QoL are similar in <40y pts and >\=40 y pts. #ESMO2024#natalee
T-DXd progressively releases linker/payload while in the circulation, converting from DAR=8 ➡️DAR=4 at 1 week ➡️DAR=2.5 at 3 weeks. The sustained release of DXd likely accounts at least in part for its efficacy and side effects. Study by @DaiichiSankyo.
https://t.co/PuAd7pqHdI
Novel endocrine therapies: What is next in HR+/HER2- breast cancer? - Just out in CTR. Perfectly on time ahead of the upcoming session on this topic at ESMO Breast 😉hope you’ll enjoy the reading. See you in Berlin🇩🇪 @myESMO https://t.co/L03NLktBDv